Logo Image
Opinion|Videos|May 19, 2025

Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

Research reveals that lower PSA levels in metastatic hormone-sensitive prostate cancer significantly delay disease progression and improve patient outcomes.

Episodes in this series

Ultra-Low PSA Responses and Clinical Outcomes

Key Themes:

  • Correlation between achieving PSA <0.02 ng/mL and clinical outcomes
  • Impact on time to progression and radiographic progression-free survival (rPFS)
  • Overall survival trends in relation to PSA response

Expert Insights:

  • Dr Shore presented data demonstrating that patients achieving ultra-low PSA levels (<0.02 ng/mL) experienced improved clinical outcomes.

The analysis showed correlations between ultra-low PSA and important end points including time to progression, rPFS, and overall survival trends

Related Content

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies
Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

View more
Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis
Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

View more